You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at www.oncopeptides-us.com
June 15, 2020
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA. See posters below.